Aidan King, MBA, CFA

Managing Partner & Co-Founder, Fountain Healthcare Partners – Board member

Aidan, qualified by training as a pharmacist from Trinity College Dublin, enjoys the challenge presented by investing in a rapidly changing life science market. Aidan started his industry career at Elan in pharmaceutical strategic marketing before moving to New York to work in Elan’s corporate venture capital group, where investments included Quadrant Healthcare (acquired by Elan, 2000), Atrix laboratories (acquired by QLT, 2004), Idun Pharmaceuticals (acquired by Pfizer, 2005) and Zealand Pharmaceuticals (IPO, 2010).
Aidan primarily focuses on US investments, marketing and fund raising and he currently sits on the boards of Xylocor Therapeutics and Corteria Pharmaceuticals. Previously, he was the firm’s representative on the boards of Syndesi Therapeutics (acquired by Abbvie, 2022), Civitas Therapeutics (acquired by Acorda, 2014), Chrono Therapeutics, Velicept Therapeutics and Palyon Medical

 

the Management team

CEO & Chairman

Head of Medicinal Chemistry

Head of Biology & Pharmacology

Scientific Founder

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors​

President and CEO, Notch Therapeutics - Independent Board member

CEO & Chairman

CEO, Domain Therapeutics - Board member

Founder & CEO of Parthenon Therapeutics - Board member

Managing partner, Kurma Life Sciences Partners - Board member

Principal, Kurma Life Sciences Partners - Board member

Managing Partner & Co-Founder, Fountain Healthcare Partners - Board member

Senior Associate, Fountain Healthcare Partners - Board observer

Scientific and Clinical Advisors

Chairman of the Scientific Advisory Board

Stanford Univ, School of Med (US) | Rheumatology-SLE

John Hopkins Medicine (US) | Rheumatology-SLE

UMC Amsterdam (NL) | Rheumatology-SLE

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam

Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow

Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal